3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
2
Tumor-Agnostic
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Recurrence
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
Paclitaxel
35
Bevacizumab
31
Carboplatin
29
pembrolizumab
25
Specimen Handling
20
Magnetic Resonance Spectroscopy
18
olaparib
16
Cisplatin
15
liposomal doxorubicin
13
Taxes
12
Immunoglobulin G
11
Gemcitabine
11
Disulfides
11
Topotecan
9
Nivolumab
9
Cyclophosphamide
9
Biopsy
8
fludarabine
7
Doxorubicin
7
mirvetuximab soravtansine
6
niraparib
5
Radiation
5
Oxaliplatin
5
Fulvestrant
5
Fluorouracil
5
trastuzumab deruxtecan
4
durvalumab
4
cediranib
4
Platinum
4
Megestrol Acetate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Palliative Care
×
Gynecologic
×
30 days
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled